Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer

Status Terminated

Clinical Trial Summary

This is a Phase I, dose finding, multicentre study evaluating the maximal tolerated dose of Glivec® in combination with mFOLFOX-Avastin®. Patients will be enrolled into each dose level in 3 patient cohorts. Additional cohorts will be enrolled, or dose levels opened, subject to the toxicities observed. Once the MTD has been determined the dose level below will be re-opened and extra patients, to a total of 15, will be enrolled.

Clinical Trial Description

n/a

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01271166
Study type	Interventional
Source	Novartis
Contact
Status	Terminated
Phase	Phase 1
Start date	October 2007

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05028933` - IMC001 for Clinical Research on Advanced Digestive System Malignancies	Phase 1
Recruiting	`NCT06200363` - A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer	Phase 1
Not yet recruiting	`NCT02923622` - Efficacy and Safety Evaluation of Traditional Chinese Medicine in the Treatment of Advanced Colorectal Cancer	N/A
Completed	`NCT01723969` - Screening Platform for Clinical Trials in Advanced Colorectal Cancer
Active, not recruiting	`NCT00309179` - A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors	Phase 2
Completed	`NCT03699111` - Identification of New Patient Stratification Tools in MSS RAS mt mCRC
Not yet recruiting	`NCT02826837` - LEAC-102 for Advanced Colorectal Cancer	Phase 1/Phase 2
Recruiting	`NCT05077839` - Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC	Phase 2
Recruiting	`NCT04324476` - A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer	Phase 2
Not yet recruiting	`NCT06369259` - Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer	Phase 2
Completed	`NCT00707889` - Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer	Phase 2
Completed	`NCT00386828` - Chemoradiation for Locally Advanced and Low Rectal Cancers: Avastin-Capecitabine-Oxaliplatin-Radiation REctal Cancer Trial	Phase 2
Recruiting	`NCT04764006` - Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study	Phase 2
Active, not recruiting	`NCT04835324` - Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study
Active, not recruiting	`NCT02619435` - Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer	Phase 2
Completed	`NCT01822444` - ANGIOPREDICT. ICORG 12-16, V3
Completed	`NCT00498407` - A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer	Phase 2
Recruiting	`NCT05731336` - A Prospective Cohort Study of Advanced Colorectal Cancer Treated With Oxaliplatin and Irinotecan.
Active, not recruiting	`NCT04744831` - Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer	Phase 2
Terminated	`NCT03311750` - Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer	Phase 2